This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Moody's Places Amgen Debt on Review

Last week's Food and Drug Administration advisory panel on Amgen's (AMGN) Aranesp for chemotherapy-induced anemia led one debt rating agency to rethink the drugmaker's debt rating.

Moody's placed the Thousand Oaks, Calif.- based company's A2 long-term and Prime-1 short term ratings -- approximately $11.2 billion of rated debt -- under review for possible downgrade on Monday.

Last week an FDA advisory panel recommended that anemia drugs such as Aranesp and Johnson & Johnson's (JNJ) Procrit be further limited in their use in cancer patients, based on evidence of negative side effects.

The panel determined the drugs should not be used in patients with metastatic breast cancer or cancer of the head and neck, and voted to bar the use of anemia drugs in cancer patients with "curative" disease. The panel did vote against entirely restricting the use of anemia drugs in cancer, and also voted down a suggestion that the drug only be used in patients with small cell lung cancer.

The ruling has the potential to weigh most heavily on Amgen, which counts on Aranesp as its top-selling drug.

"Although the panel recommendation does not represent a worst-case scenario, Moody's has previously stated that Amgen's key credit ratios may not have sufficient cushion to absorb any further decline in Aranesp sales at the current rating level," according to a Moody's press release.

Moody's said concern about Amgen's late-stage pipeline, emerging competitive pressures, and Amgen's history of share repurchases and acquisitions that have stressed its credit ratios also played into the decision for a rating review.

It will consider the anticipated decline in Aranesp sales, potential of cost saving initiatives, opportunities for revenue growth (such as osteoperosis candidate denosumab) and the company's financial policies.

Moody's revised its ratings outlook for Amgen to negative from stable in May of last year.

Amgen's shares closed down 3.1% at 43.08 on Monday.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,372.15 -8.26 -0.05%
S&P 500 1,895.80 +9.04 0.48%
NASDAQ 4,293.0710 +34.6330 0.81%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs